Anupam Rasayan India Ltd. AI Stock Analysis
Want to see IN:ANURAS full AI Analyst Report?
Anupam Rasayan India Ltd. (ANURAS) AI Stock Analysis
Anupam Rasayan India Ltd.
(NSE:ANURAS)
The score is supported primarily by a generally sound balance sheet, revenue growth, and strong technical momentum. Margin deterioration and especially weak cash generation are significant financial risks, while the high P/E ratio and minimal dividend yield weigh heavily on valuation.
Anupam Rasayan India Ltd. (ANURAS) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 148.07B
- Dividend Yield
- 0.11%
- Average Volume (3M)
- 13.45K
- Price to Earnings (P/E)
- 71.2
- Beta (1Y)
- 0.63
- Revenue Growth
- 23.80%
- EPS Growth
- 16.11%
- Country
- India
- Employees
- 2,606
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals - Specialty
Anupam Rasayan India Ltd. Business Overview & Revenue Model
Company Description
Anupam Rasayan India Ltd., established in Surat, India, in 1984, specializes in the custom synthesis and production of specialty chemicals. The company manufactures a diverse range of life science-oriented chemicals, including intermediates and activ...
Anupam Rasayan India Ltd. Financial Statement Overview
Summary
Revenue and net profit growth, together with a healthy balance sheet and moderate leverage, support the score. However, margin compression, declining returns on equity, and consistently weak or negative free cash flow materially reduce financial strength.
Income Statement
72PositiveBalance Sheet
78PositiveCash Flow
46Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.24B | 23.65B | 14.42B | 14.80B | 16.02B | 10.74B |
| Gross Profit | 11.33B | 8.16B | 8.22B | 8.51B | 8.85B | 7.02B |
| EBITDA | 6.35B | 5.43B | 4.07B | 3.87B | 4.32B | 3.05B |
| Net Income | 1.80B | 1.70B | 933.49M | 1.29B | 1.81B | 1.52B |
Balance Sheet | ||||||
| Total Assets | 113.95B | 80.13B | 52.69B | 46.02B | 37.78B | 28.91B |
| Cash, Cash Equivalents and Short-Term Investments | 8.23B | 4.11B | 1.35B | 3.48B | 6.67B | 618.77M |
| Total Debt | 25.33B | 18.67B | 13.73B | 10.70B | 8.22B | 8.36B |
| Total Liabilities | 41.99B | 33.83B | 21.87B | 16.71B | 12.70B | 11.64B |
| Stockholders Equity | 50.48B | 33.34B | 28.50B | 27.61B | 23.73B | 17.27B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -3.57B | -4.40B | -6.57B | 713.03M | -3.18B |
| Operating Cash Flow | 0 | 1.99B | -301.25M | 590.32M | 2.92B | -1.71B |
| Investing Cash Flow | 0 | -8.21B | -3.30B | -3.92B | -5.23B | -4.12B |
| Financing Cash Flow | 0 | 7.57B | 2.23B | 3.95B | 3.71B | 3.84B |
Anupam Rasayan India Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ANURAS, the sentiment is Positive. The current price of 1302.25 is above the 20-day moving average (MA) of 1155.53, above the 50-day MA of 1175.98, and above the 200-day MA of 1250.25, indicating a bullish trend. The MACD of 14.84 indicates Negative momentum. The RSI at 73.68 is Negative, neither overbought nor oversold. The STOCH value of 85.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ANURAS.
Anupam Rasayan India Ltd. Peers Comparison
Overall Rating
IN:AETHER71Outperform
IN:ATUL68Neutral
IN:ALKYLAMINE65Neutral- IN:ANURAS63Neutral
IN:JUBLINGREA53Neutral
IN:AARTIIND47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:AETHER | 71Outperform | INR 224.04B | 89.12 | ― | ― | 30.76% | 28.12% |
| IN:ATUL | 68Neutral | INR 153.30B | 19.70 | ― | 0.58% | 18.15% | 42.38% |
| IN:ALKYLAMINE | 65Neutral | INR 82.28B | 33.56 | ― | 0.62% | 13.38% | 35.82% |
| IN:ANURAS | 63Neutral | INR 136.71B | 71.23 | ― | 0.11% | 23.80% | 16.11% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:JUBLINGREA | 53Neutral | INR 95.55B | 26.64 | ― | 0.84% | 15.41% | 21.76% |
| IN:AARTIIND | 47Neutral | INR 175.55B | 29.46 | ― | 0.21% | 39.85% | 103.71% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ANURAS | Anupam Rasayan India Ltd. | 1302.25 | 218.18 | 20.13% | |
| IN:AARTIIND | AARTI Industries Ltd | 481.85 | 87.48 | 22.18% | |
| IN:AETHER | Aether Industries Ltd. | 1675.75 | 828.30 | 97.74% | |
| IN:ALKYLAMINE | Alkyl Amines Chemicals Limited | 1623.90 | -161.33 | -9.04% | |
| IN:ATUL | Atul Limited | 5166.40 | -819.40 | -13.69% | |
| IN:JUBLINGREA | Jubilant Ingrevia Ltd. | 592.35 | -120.79 | -16.94% |
Anupam Rasayan India Ltd. Corporate Events
Anupam Rasayan Announces Investor Conference Schedule
Anupam Rasayan India Ltd. is identified in the release, but its industry and products are not described. Company officials are scheduled to attend JM Financials India Xchange 2026 Conference on November 16, 2026, at Hotel Trident, BKC, Mumbai, for ph...
Anupam Rasayan Revises Consolidated EPS After Formula Error
Anupam Rasayan India operates in the specialty chemicals industry, producing solutions for life-sciences and agrochemical applications, with a focus on serving industrial and global markets. The company submitted revised unaudited standalone and cons...
Anupam Rasayan Schedules Q2 and H1 FY27 Earnings Call
Anupam Rasayan India Ltd. announced that it will hold an earnings call on November 6, 2026, to discuss its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The release does not provide de...
Anupam Rasayan Secures Majority Control in Bliss GVS Pharma
Anupam Rasayan India Ltd. has completed the acquisition of a controlling stake in Bliss GVS Pharma Ltd., culminating a series of transactions under a previously announced share purchase agreement and open offer. Following on-market purchases and tend...
Anupam Rasayan Executes Security Documents Backing MVCPL Debentures
Anupam Rasayan India Ltd. has executed a debenture trust deed involving Mates Visa Consultancy Pvt. Ltd. and Catalyst Trusteeship Ltd., as part of a security package linked to debentures issued by MVCPL. The move formalizes arrangements under a previ...
Anupam Rasayan Pledges MVCPL Stake and Issues Corporate Guarantee for Debenture Structure
Anupam Rasayan India Ltd. has executed a debenture trust deed involving Mates Visa Consultancy Pvt. Ltd., Catalyst Trusteeship Ltd., and the debenture holders, formalising security arrangements around MVCPL’s debentures. As part of this structure, th...
Anupam Rasayan Raises INR 145 Crore via Secured Debenture Issue
Anupam Rasayan India Ltd. has allotted 14,500 senior secured, rated, unlisted, redeemable non-convertible debentures with a face value of INR 1,00,000 each, raising INR 145 crore from Aditya Birla Capital Ltd. The issuance, executed through a debentu...
Anupam Rasayan Board Clears INR 160 Crore NCD Issue for Debt Refinancing
Anupam Rasayan India Ltd.’s board has approved the private placement of up to 16,000 secured, rated, unlisted, redeemable non-convertible debentures, with a total size not exceeding INR 160 crore. The debentures will be issued in dematerialised form...
Anupam Rasayan to Raise ₹160 Crore via Secured Non-Convertible Debentures
Anupam Rasayan India Ltd.’s board has approved the issuance of up to 16,000 secured, rated, unlisted and redeemable non-convertible debentures, each with a nominal value of ₹100,000, for a total amount not exceeding ₹160 crore on a private placement...
Anupam Rasayan Files Q1 FY27 Results, Appoints New COO
Anupam Rasayan India Ltd. reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following a board meeting held on August 14. The results have undergone a limited review by the statutory auditor, who...
Anupam Rasayan Elevates Ravi Desai to Chief Operating Officer
Anupam Rasayan India Ltd. has appointed Ravi Desai as Chief Operating Officer, effective August 14, 2026, following approval by the board based on the Nomination and Remuneration Committee’s recommendation. Desai, who has been with the company since...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026